BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32128966)

  • 1. Addition of [
    John BV; Aubuchon S; Dahman B; Konjeti VR; Heuman D; Hubert J; Thomas S; Deng Y; Solomon C; Sundaram LT; Love E; Singal AG; Tatum JL
    Liver Transpl; 2020 Jun; 26(6):774-784. PubMed ID: 32128966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.
    Chalaye J; Costentin CE; Luciani A; Amaddeo G; Ganne-Carrié N; Baranes L; Allaire M; Calderaro J; Azoulay D; Nahon P; Seror O; Mallat A; Soussan M; Duvoux C; Itti E; Nault JC
    J Hepatol; 2018 Aug; 69(2):336-344. PubMed ID: 29518452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study.
    Hyun SH; Eo JS; Lee JW; Choi JY; Lee KH; Na SJ; Hong IK; Oh JK; Chung YA; Song BI; Kim TS; Kim KS; Moon DH; Yun M
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1638-45. PubMed ID: 26936852
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Na SJ; Oh JK; Hyun SH; Lee JW; Hong IK; Song BI; Kim TS; Eo JS; Lee SW; Yoo IR; Chung YA; Yun M
    J Nucl Med; 2017 May; 58(5):730-736. PubMed ID: 27789714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma.
    Yoon KT; Kim JK; Kim DY; Ahn SH; Lee JD; Yun M; Rha SY; Chon CY; Han KH
    Oncology; 2007; 72 Suppl 1():104-10. PubMed ID: 18087190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma?
    Cho Y; Lee DH; Lee YB; Lee M; Yoo JJ; Choi WM; Cho YY; Paeng JC; Kang KW; Chung JK; Yu SJ; Lee JH; Yoon JH; Lee HS; Kim YJ
    PLoS One; 2014; 9(8):e105679. PubMed ID: 25153834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization.
    Kim MJ; Kim YS; Cho YH; Jang HY; Song JY; Lee SH; Jeong SW; Kim SG; Jang JY; Kim HS; Kim BS; Lee WH; Park JM; Lee JM; Lee MH; Choi DL
    Korean J Intern Med; 2015 May; 30(3):308-15. PubMed ID: 25995661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidentally found parotid gland lesion in
    Jung JH; Lee YS; Jung YH; Choi SH; Nam SY; Cho HJ; Kwon M
    BMC Surg; 2024 Apr; 24(1):124. PubMed ID: 38658868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
    Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
    Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis.
    Lee JW; Yun M; Cho A; Han KH; Kim DY; Lee SM; Lee JD
    Ann Nucl Med; 2015 Jun; 29(5):400-8. PubMed ID: 25652647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection.
    Morio K; Kawaoka T; Aikata H; Namba M; Uchikawa S; Kodama K; Ohya K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Nakamura Y; Akagi M; Awai K; Kobayashi T; Ohdan H; Chayama K
    Eur J Radiol; 2020 Mar; 124():108828. PubMed ID: 31955034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [
    Bak-Fredslund KP; Keiding S; Villadsen GE; Kramer S; Schlander S; Sørensen M
    Liver Int; 2020 Feb; 40(2):447-455. PubMed ID: 31705784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade.
    Wolfort RM; Papillion PW; Turnage RH; Lillien DL; Ramaswamy MR; Zibari GB
    Int Surg; 2010; 95(1):67-75. PubMed ID: 20480845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers.
    Takeuchi S; Rohren EM; Abdel-Wahab R; Xiao L; Morris JS; Macapinlac HA; Hassan MM; Kaseb AO
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):969-978. PubMed ID: 27942837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma.
    Lee M; Jeon JY; Neugent ML; Kim JW; Yun M
    Clin Exp Metastasis; 2017 Apr; 34(3-4):251-260. PubMed ID: 28429188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma.
    Refaat R; Basha MAA; Hassan MS; Hussein RS; El Sammak AA; El Sammak DAEA; Radwan MHS; Awad NM; Saad El-Din SA; Elkholy E; Ibrahim DRD; Saleh SA; Montasser IF; Said H
    Eur Radiol; 2018 Dec; 28(12):5356-5367. PubMed ID: 29948070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET CT as a prognostic factor in hepatocellular carcinoma.
    Cho E; Jun CH; Kim BS; Son DJ; Choi WS; Choi SK
    Turk J Gastroenterol; 2015 Jul; 26(4):344-50. PubMed ID: 26039005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Impact of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma.
    Lee SD; Kim SH; Kim SK; Kim YK; Park SJ
    Transplantation; 2015 Oct; 99(10):2142-9. PubMed ID: 25905981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of pretreatment PET/CT lean body mass-corrected parameters in patients with hepatocellular carcinoma.
    Sun M; Zhang G; Guo J; Hao S; Wang Z; Fan G
    Nucl Med Commun; 2018 Jun; 39(6):564-571. PubMed ID: 29634658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.
    Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ
    Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.